Lv2
110 积分 2024-11-17 加入
Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first‐line treatment for primary central nervous system lymphoma: A prospective, open‐label, multicentre clinical trial
17小时前
待确认
Rilzabrutinib: First Approval
20天前
已完结
Systematic review of real-world data on the effectiveness and safety profiles of first-line therapies in chronic lymphocytic leukemia
21天前
已关闭
Hypophosphatemia related to the use of ibrutinib
21天前
已完结
HSR26-204: Baseline EORTC QLQ-C30 “Clinically Important” Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials
1个月前
已关闭
Skin toxicities related to Bruton tyrosine kinase inhibitors: an updated review
1个月前
已完结
Rilzabrutinib
2个月前
已完结
A first‐line regimen combining Bruton's tyrosine kinase and programmed cell death protein‐1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma
2个月前
已完结
Aligning patient‐reported priorities in immune thrombocytopenia with clinical and regulatory advances: Insights from rilzabrutinib
4个月前
已完结
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study
4个月前
已关闭
皖公网安备34019202002308
